{"title":"不同序列mFOLFIRINOX（或SOXIRI）和吉西他滨加白蛋白结合紫杉醇治疗不可切除胰腺癌的疗效和安全性","authors":"Silan Huang, Lingli Huang, Dongsheng Zhang, Qi Jiang, Fenghua Wang, Guifang Guo","doi":"10.2147/ITT.S530434","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to evaluate and compare the therapeutic efficacy and adverse effects of two sequential treatment strategies in patients with unresectable advanced pancreatic cancer (aPC), albumin-bound-paclitaxel plus gemcitabine administered follow by mFOLFIRINOX or SOXIRI (AG-F(S)FX<sub>m</sub>) versus the reverse sequence regimen F(S)FX<sub>m</sub>-AG.</p><p><strong>Methods: </strong>In this retrospective analysis, patients with unresectable advanced pancreatic cancer (aPC) who received either AG-F(S)FX<sub>m</sub> or F(S)FX<sub>m</sub>-AG were included. Key endpoints were overall survival (OS), progression-free survival (PFS), and treatment-related toxicity. Survival outcomes were assessed using Kaplan-Meier curves, and differences between groups were examined through hazard ratios (HR) and corresponding p-values.</p><p><strong>Results: </strong>A total of 107 patients were analyzed, including 49 who underwent AG-F(S)FX<sub>m</sub> and 58 who received F(S)FX<sub>m</sub>-AG. The median OS was 14.60 months for F(S)FX<sub>m</sub>-AG and 12.20 months for AG-F(S)FX<sub>m</sub> (HR: 1.04, 95% CI: 0.69-1.57, p= 0.86). Median PFS1, median PFS2 and median total PFS (tPFS) were 5.20 months versus 4.83 months (HR: 0.81, 95% CI: 0.54-1.21, p= 0.3), 4.53 months versus 5.77 months (HR: 1.15, 95% CI: 0.71-1.88, p= 0.60) and 13.80 months versus 12.80 months (HR: 0.90, 95% CI: 0.55-1.48, p= 0.67) for F(S)FX<sub>m</sub>-AG versus AG-F(S)FX<sub>m</sub>. Given their comparable efficacy, we further compared the safety profiles of both regimens. The toxicity profiles differed between the two sequential treatments. Leukopenia was more common with first-line AG, while gastrointestinal toxicity, fatigue, and sensory neuropathy were more frequent with first-line F(S)FX<sub>m</sub>. Additionally, elevated aspartate aminotransferase was more often reported with second-line AG.</p><p><strong>Conclusion: </strong>Both AG-F(S)FX<sub>m</sub> and F(S)FX<sub>m</sub>-AG demonstrated comparable efficacy in treating aPC, with F(S)FX<sub>m</sub>-AG showing a trend toward improved outcomes. The choice of sequential treatment should be guided by toxicity profiles and patient-specific factors. Further prospective studies are warranted to optimize treatment sequencing and personalize therapy for improved patient outcomes.</p>","PeriodicalId":30986,"journal":{"name":"ImmunoTargets and Therapy","volume":"14 ","pages":"1097-1110"},"PeriodicalIF":4.4000,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12499572/pdf/","citationCount":"0","resultStr":"{\"title\":\"Efficacy and Safety of Different Sequences for mFOLFIRINOX (or SOXIRI) and Gemcitabine Plus Albumin-Bound Paclitaxel in Unresectable Pancreatic Cancer.\",\"authors\":\"Silan Huang, Lingli Huang, Dongsheng Zhang, Qi Jiang, Fenghua Wang, Guifang Guo\",\"doi\":\"10.2147/ITT.S530434\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>This study aimed to evaluate and compare the therapeutic efficacy and adverse effects of two sequential treatment strategies in patients with unresectable advanced pancreatic cancer (aPC), albumin-bound-paclitaxel plus gemcitabine administered follow by mFOLFIRINOX or SOXIRI (AG-F(S)FX<sub>m</sub>) versus the reverse sequence regimen F(S)FX<sub>m</sub>-AG.</p><p><strong>Methods: </strong>In this retrospective analysis, patients with unresectable advanced pancreatic cancer (aPC) who received either AG-F(S)FX<sub>m</sub> or F(S)FX<sub>m</sub>-AG were included. Key endpoints were overall survival (OS), progression-free survival (PFS), and treatment-related toxicity. Survival outcomes were assessed using Kaplan-Meier curves, and differences between groups were examined through hazard ratios (HR) and corresponding p-values.</p><p><strong>Results: </strong>A total of 107 patients were analyzed, including 49 who underwent AG-F(S)FX<sub>m</sub> and 58 who received F(S)FX<sub>m</sub>-AG. The median OS was 14.60 months for F(S)FX<sub>m</sub>-AG and 12.20 months for AG-F(S)FX<sub>m</sub> (HR: 1.04, 95% CI: 0.69-1.57, p= 0.86). Median PFS1, median PFS2 and median total PFS (tPFS) were 5.20 months versus 4.83 months (HR: 0.81, 95% CI: 0.54-1.21, p= 0.3), 4.53 months versus 5.77 months (HR: 1.15, 95% CI: 0.71-1.88, p= 0.60) and 13.80 months versus 12.80 months (HR: 0.90, 95% CI: 0.55-1.48, p= 0.67) for F(S)FX<sub>m</sub>-AG versus AG-F(S)FX<sub>m</sub>. Given their comparable efficacy, we further compared the safety profiles of both regimens. The toxicity profiles differed between the two sequential treatments. Leukopenia was more common with first-line AG, while gastrointestinal toxicity, fatigue, and sensory neuropathy were more frequent with first-line F(S)FX<sub>m</sub>. Additionally, elevated aspartate aminotransferase was more often reported with second-line AG.</p><p><strong>Conclusion: </strong>Both AG-F(S)FX<sub>m</sub> and F(S)FX<sub>m</sub>-AG demonstrated comparable efficacy in treating aPC, with F(S)FX<sub>m</sub>-AG showing a trend toward improved outcomes. The choice of sequential treatment should be guided by toxicity profiles and patient-specific factors. Further prospective studies are warranted to optimize treatment sequencing and personalize therapy for improved patient outcomes.</p>\",\"PeriodicalId\":30986,\"journal\":{\"name\":\"ImmunoTargets and Therapy\",\"volume\":\"14 \",\"pages\":\"1097-1110\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2025-10-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12499572/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ImmunoTargets and Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/ITT.S530434\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ImmunoTargets and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/ITT.S530434","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Efficacy and Safety of Different Sequences for mFOLFIRINOX (or SOXIRI) and Gemcitabine Plus Albumin-Bound Paclitaxel in Unresectable Pancreatic Cancer.
Aim: This study aimed to evaluate and compare the therapeutic efficacy and adverse effects of two sequential treatment strategies in patients with unresectable advanced pancreatic cancer (aPC), albumin-bound-paclitaxel plus gemcitabine administered follow by mFOLFIRINOX or SOXIRI (AG-F(S)FXm) versus the reverse sequence regimen F(S)FXm-AG.
Methods: In this retrospective analysis, patients with unresectable advanced pancreatic cancer (aPC) who received either AG-F(S)FXm or F(S)FXm-AG were included. Key endpoints were overall survival (OS), progression-free survival (PFS), and treatment-related toxicity. Survival outcomes were assessed using Kaplan-Meier curves, and differences between groups were examined through hazard ratios (HR) and corresponding p-values.
Results: A total of 107 patients were analyzed, including 49 who underwent AG-F(S)FXm and 58 who received F(S)FXm-AG. The median OS was 14.60 months for F(S)FXm-AG and 12.20 months for AG-F(S)FXm (HR: 1.04, 95% CI: 0.69-1.57, p= 0.86). Median PFS1, median PFS2 and median total PFS (tPFS) were 5.20 months versus 4.83 months (HR: 0.81, 95% CI: 0.54-1.21, p= 0.3), 4.53 months versus 5.77 months (HR: 1.15, 95% CI: 0.71-1.88, p= 0.60) and 13.80 months versus 12.80 months (HR: 0.90, 95% CI: 0.55-1.48, p= 0.67) for F(S)FXm-AG versus AG-F(S)FXm. Given their comparable efficacy, we further compared the safety profiles of both regimens. The toxicity profiles differed between the two sequential treatments. Leukopenia was more common with first-line AG, while gastrointestinal toxicity, fatigue, and sensory neuropathy were more frequent with first-line F(S)FXm. Additionally, elevated aspartate aminotransferase was more often reported with second-line AG.
Conclusion: Both AG-F(S)FXm and F(S)FXm-AG demonstrated comparable efficacy in treating aPC, with F(S)FXm-AG showing a trend toward improved outcomes. The choice of sequential treatment should be guided by toxicity profiles and patient-specific factors. Further prospective studies are warranted to optimize treatment sequencing and personalize therapy for improved patient outcomes.
期刊介绍：
Immuno Targets and Therapy is an international, peer-reviewed open access journal focusing on the immunological basis of diseases, potential targets for immune based therapy and treatment protocols employed to improve patient management. Basic immunology and physiology of the immune system in health, and disease will be also covered.In addition, the journal will focus on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
